Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
EPS $-52.45 · Revenue $0.00
EPS $-118.37 · Revenue $0.00
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $0 | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-35.8M | -288.1% | -153.3% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | — | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | — | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | — | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-16.3M | -686.8% | -4.8% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | — | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | -55.6% | -37.4% | -16.1% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 0.17x | +3615.8% | +30.9% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $3.8M | +22.8% | +20.9% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | — | — | — | — |
| Revenue Surprise | — | — | — | — |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | HRT FINANCIAL LP | 10 percent owner | Common Stock | D | 18,395 | $5.94 |
| Aug 14, 2026 | HRT FINANCIAL LP | 10 percent owner | Common Stock | D | 3,163 | $0.90 |
| Aug 13, 2026 | HRT FINANCIAL LP | 10 percent owner | Common Stock | D | 42,411 | $0.89 |
| Aug 12, 2026 | Knechtel Fred S. | officer: Chief Financial Officer | Common Stock | A | 301,991 | $4.28 |
| Aug 12, 2026 | Knechtel Fred S. | officer: Chief Financial Officer | Convertible Promissory Note | D | 0 | $4.28 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Ben Chung-Bin Hwang | Chief Executive Officer & Chairman | USD 2,300,000 | — | 1968 | Active |
Chung-Bin Hwang | President | USD 2,300,000 | — | 1968 | Active |
Jack E. Stover | Chief Executive Officer & Chairman | USD 2,300,000 | Male | 1953 | Active |
Fred S. Knechtel | Chief Financial Officer | USD 851,602 | Male | 1961 | Active |
Sean Givens | Head of Government Business | — | Male | — | Active |
David Icke | Head of Digital Health Business | — | Male | — | Active |
William McMillan | Co-founder, Chief Scientific Officer & Head of Research | — | Male | 1951 | Active |
Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of which $4.57 million was converted into Series A Convertible Preferred Stock
BERKELEY, California, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a one-for-four (1:4) reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on August 17, 2026, and the Company's common stock will open for trading on The Nasdaq Capital Market on August 17, 2026 on a post-split basis, under the existing ticker symbol “PFSA” but with a new CUSIP number 74319X405.
BERKELEY, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of an Option Agreement (the “Agreement”) which provides Profusa the right and option, but not the obligation, subject to satisfaction of the conditions described below, to acquire G3 Vision Labs, Inc. (“G3”) and its subsidiaries, Med Screen Laboratories Inc., Dominion Diagnostics LLC and Acutis Diagnostics Inc. G3's 2025 Net Revenues are estimated, based on unaudited management information, to be approximately $111 million.
BERKELEY, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of a non-binding term sheet with a privately held, commercial-stage health diagnostics and toxicology testing company (the "Dx Company").
BERKELEY, California, July 02, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a one-for-twenty-five (1:25) reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on July 7, 2026, and the Company's common stock will open for trading on The Nasdaq Global Market on July 7, 2026 on a post-split basis, under the existing ticker symbol “PFSA” but with a new CUSIP number 74319X 306.
